NCT01426828

Id-KLH Vaccine + T Cells

Conditions: Multiple Myeloma
Sponsors: Abramson Cancer Center of the University of Pennsylvania
Phase 2

NCT01174082

Donor Lymphocyte Infusion for Myeloma

Conditions: Myeloma
Sponsors: M.D. Anderson Cancer Center
Phase 2

NCT00988312

Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma

Conditions: Multiple Myeloma, Plasmocytoma
Sponsors: University Hospital Carl Gustav Carus
Phase I

NCT00878410

Immunoglobulin and QS-21 in Patients With Follicular Lymphomas 

Conditions: Lymphoma
Sponsors: National Cancer Institute (NCI)
Phase I

NCT00621036

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Conditions: Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
Sponsors: Simmons Cancer Center
Phase II

NCT00574886

Idiotype Vaccine Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients With Lymphoma Who Had Failed Induction Chemotherapy

Conditions: Lymphoma
Sponsors: University of Nebraska
Phase n/a 

NCT00510471

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Conditions: Non-Hodgkin's Lymphoma
Sponsors: Genitope Corporation
Phase II

NCT00490529

Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Conditions: Lymphoma, Mantle-Cell
Sponsors: Stanford University
Phase II

NCT00019097

Vaccine Therapy in Treating Patients With Multiple Myeloma

Conditions: Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
Sponsors: National Cancer Institute (NCI)
Phase II

NCT00324831

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Conditions: Lymphoma
Sponsors: Favrille
Phase III